HHS Taps OraSure For Ebola Diagnostics Contract
This article was originally published in The Gray Sheet
The rapid diagnostics firm was awarded a contract to develop a rapid, point-of-care assay for Ebola from the Biomedical Advanced Research and Development Authority.
You may also be interested in...
October’s approvals include the US FDA approval of Myriad’s myChoice CDx companion diagnostic for GlaxoSmithKline’s ovarian cancer drug and the approval or Medtronic’s Valiant Navion thoracic stent graft system in Japan.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.